Mar. 27 at 10:29 PM
$XBI,
$PSTV,
$SLS &
$DRTS - Nice to see green candle on XBI today. Onward & upward from here! CEO Marc Hedrick just stated he sees PSTV selling 500,000 CNSide Assays per year once their commercial selling system is fully staffed & set up. Previously, PSTV contracted to pay BIOCQ
$2800 per test (https://www.businesswire.com/news/home/20230907484834/en/Biocept-Signs-CNSide-Licensing-Agreement-with-Plus-Therapeutics) with plans to resell same B2B. That means they would sell the test for >
$5000 each to cover all expenses, payroll, licensing etc. So, 1 year from now CEO is projecting 500,000 sales at
$5K each or more = sales of at least
$25MM a huge game-changer for PSTV Year 1. If you do the math
$250MM is obtainable, but I'm happy with
$10-
$25MM in year 1 after commercial effort is fully established. Then after that it will be the same Oncologists, Immunologists & ER Doctors reordering more CNSide assays to help them save lives. PSTV is funded through mid 2026 now. PSTV execs are saving huge news to slay SS. Smart! PSTV, SLS & DRTS longs will see
$12/share! Hold for the gold.
